ProCE Banner Activity

Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF

Slideset Download
Conference Coverage

Ropeginterferon alfa-2b treatment of patients with low/intermediate-1–risk, prefibrotic primary myelofibrosis shows early evidence of promising efficacy and a safety profile warranting further study.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen